Coherus BioSciences (CHRS) Q2 2026: Loctorsi Eyes $15M Quarter as SG&A Drops for Sixth Straight Period

Summary

• Loctorsi Growth Engine: Physician adoption and education drive durable revenue momentum as new accounts and repeat use expand.
• Cost Structure Reset: Six consecutive quarters of SG&A declines reflect a leaner, focused operating model post-divestiture.
• Pipeline Data Catalyst: October clinical readouts for Tegmo Ketog and Castozo Ketog will determine future growth trajectory.

Business Overview

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on oncology and immunotherapy. The company’s core revenue driver is Loctorsi, a targeted therapy for nasopharyngeal carcinoma (NPC), supported by a pipeline including Tegmo Ketog and Castozo Ketog, both immuno-oncology candidates. Revenue is generated through product sales, with Loctorsi now central after the 2025 divestiture of the biosimilar Udenica franchise, which also enabled significant deleveraging and cost reduction.

Performance Analysis

Loctorsi net revenue rose in line with expectations, underpinned by a dual-pronged strategy of expanding both breadth and depth of physician adoption. The team reported the highest number of new patient starts since launch and highlighted a gradual but steady increase in treatment duration, despite persistent headroom in both new patient starts and appropriate dosing. Management reaffirmed a $57 to $62 million revenue target for Loctorsi in 2026, with average quarterly growth expected in the 10 to 15 percent range.

Operating expenses from continuing operations fell sharply, with R&D and SG&A down $4.9 million and $5 million year-over-year, respectively, as the company’s exit from biosimilars translates to a more focused cost base. SG&A has now declined for six straight quarters. Cash burn remains a watchpoint, with $105.3 million in cash and investments at quarter-end, though management expects legacy liabilities to be substantially settled by year-end, easing cash outflows.

• Physician Conversion Drives Uptake: Targeted education and claims data analytics are enabling deeper and broader Loctorsi penetration.
• Expense Base Realignment: Lower headcount and streamlined operations post-Udenica divestiture underpin margin improvement.
• Legacy Burden Fading: Accrued liabilities and payables related to divested products dropped by over 60 percent sequentially, freeing up future cash.

Milestone earn-outs from the Udenica sale were not met in Q2, but remain possible in Q3, offering potential non-dilutive upside. Management reiterated funding sufficiency through key 2026-2027 data readouts, but near-term pipeline catalysts will be critical for sentiment and valuation.

Executive Commentary

Strategic Positioning

1. Loctorsi Commercial Execution

Loctorsi’s growth is anchored in physician education and behavioral change, leveraging six-year survival data and AI-enabled outreach. The company is systematically converting non-users, improving repeat usage, and addressing dosing misunderstandings through targeted initiatives. This dual focus on breadth (new accounts) and depth (repeat prescribing) is central to the $15 million quarterly target.

2. Cost Structure Overhaul

Post-biosimilar exit, Coherus has engineered a leaner cost base, with headcount reductions and lower R&D manufacturing spend. SG&A has dropped for six straight quarters, and management’s full-year OpEx guidance of $170–$175 million positions the company for improved operating leverage as Loctorsi scales.

3. Pipeline Readiness and Data Catalysts

Anticipated October data readouts for Tegmo Ketog and Castozo Ketog represent the next major inflection point. Management is positioning these programs to address immune resistance in cancer, and the upcoming disclosures will shape the company’s ability to diversify beyond Loctorsi and sustain long-term growth.

4. Legacy Liability Resolution

Rapid settlement of accrued rebates, reserves, and TSA payables has materially reduced cash drag. With most legacy obligations set to be extinguished by year-end, Coherus expects future cash burn to decline, enhancing capital flexibility for pipeline investment and commercial expansion.

5. Udenica Milestone Optionality

Potential milestone payments from the Udenica divestiture remain a non-core but meaningful upside lever, dependent on the buyer’s performance in upcoming quarters. While not counted on in base planning, achievement could extend the funding runway or support additional pipeline investment.

Key Considerations

Coherus enters the second half of 2026 with a streamlined business model, a maturing commercial asset in Loctorsi, and pivotal clinical catalysts on the horizon. Investors should weigh commercial momentum, cost discipline, and the timing and quality of pipeline data in assessing risk-reward.

Key Considerations:

• Loctorsi Market Penetration: Physician education and claims analytics are expanding both the breadth and depth of adoption, but awareness remains a limiting factor.
• Duration and Dosing Optimization: Correcting misdosing and extending treatment duration could unlock incremental revenue, though scale of impact is still being quantified.
• Pipeline Data as Valuation Catalyst: October disclosures for Tegmo Ketog and Castozo Ketog will determine the company’s ability to pivot from single-asset risk.
• Cash Management: Legacy liabilities are winding down, but cash burn and milestone uncertainty require close monitoring.
• SG&A and R&D Flexibility: Sustained cost discipline is essential to preserve runway and enable reinvestment as the pipeline matures.

Risks

Coherus faces concentrated risk in Loctorsi execution, with pipeline diversification contingent on unproven, near-term data. Commercial uptake depends on sustained physician conversion and proper dosing, while any delays or negative surprises in October’s clinical readouts for Tegmo Ketog and Castozo Ketog could materially impact sentiment and funding optionality. The company’s cash position is improving, but milestone payments remain uncertain, and any reacceleration in cash burn would increase financing risk.

Forward Outlook

For Q3 2026, Coherus guided to:

• Continued Loctorsi revenue growth, targeting average quarterly increases of 10–15 percent
• Further reduction in legacy liability-related cash outflows

For full-year 2026, management maintained guidance:

• Loctorsi revenue of $57–$62 million
• Combined operating expenses of $170–$175 million

Management emphasized the importance of October pipeline data readouts and expects legacy obligations to be substantially settled by year-end, positioning the company for a cleaner financial profile in 2027.

• October data readouts for Tegmo Ketog and Castozo Ketog
• Potential Udenica milestone achievement in Q3 or later

Takeaways

Coherus is executing a disciplined commercial and operational reset, with Loctorsi’s adoption curve and October’s clinical data as the twin levers for future upside or risk.

• Loctorsi’s growth is driven by methodical physician engagement and room for both new patient starts and longer therapy duration, but the pace of conversion and dosing optimization remains a watchpoint.
• Cost structure is now aligned with a focused oncology strategy, with legacy liabilities receding and SG&A at multi-year lows, giving management more flexibility for pipeline investment.
• Investors should monitor October clinical catalysts and the evolution of cash burn, as these will determine the sustainability of the current trajectory and potential for value creation beyond Loctorsi.

Conclusion

Coherus has made tangible progress in commercial execution and cost management, setting the stage for a pivotal second half centered on pipeline data. The company’s fortunes now hinge on converting Loctorsi’s potential into durable market share and delivering positive clinical results to drive diversification and long-term growth.

Industry Read-Through

Coherus’ disciplined exit from biosimilars and focus on a single commercial oncology asset is emblematic of a broader industry trend toward specialization and leaner operating models. The emphasis on physician-level claims analytics and AI-enabled education reflects a shift in commercial strategy across the sector, as companies seek to maximize the impact of limited sales resources. Pipeline-driven optionality remains a key valuation lever for small and mid-cap biotech, with near-term clinical data serving as critical inflection points for capital allocation and strategic direction. Other oncology-focused biotechs should note the importance of rapid liability resolution and operational flexibility in navigating funding cycles and market volatility.

CHRS Healthcare Biotechnology Oncology Pipeline Cost Management Immunotherapy Commercialization